Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.59 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 04/14/15 All times are local (Market data is delayed by at least 15 minutes).

zeltia sa (ZLIXF) Key Developments

Zeltia SA expected to report Q1 2015 results on May 2, 2015. This event was calculated by Capital IQ (Created on April 30, 2015).

Zeltia SA expected to report Q1 2015 results on May 2, 2015. This event was calculated by Capital IQ (Created on April 30, 2015).

Zeltia Reports Earnings Results for the First Quarter of 2015

Zeltia reported earnings results for the first quarter of 2015. For the period, the company's net profit dropped 61% to EUR 6.5 million (USD 7.1 million) compared with EUR 16.9 million in the equivalent period of 2014. Net sales in the biopharmaceutical sector amounted to EUR 21.1 million, compared with EUR 20.9 million in first-quarter 2014. The main reason for Zeltia's negative financial performance during the beginning of the year is the reduction in milestone payment under an agreement signed with Janssen in 2011 on the development of oncology product Yondelis, which for first-quarter 2015 corresponded to only USD 10 million, compared with USD 25 million in first-quarter 2014.

Zeltia SA Reports Earnings Results for the Full Year 2014

Zeltia SA reported earnings results for the full year 2014. For the year, the company reported group total revenues amounted to EUR 178 million up 8% with respect to EUR 164.7 million in 2013. Group EBITDA amounted to EUR 25.7 million, up 8% year-on-year. This improvement in operating profit was achieved despite the increase in R&D spending, which amounted to EUR 52.5 million in 2014, up 23% year-on-year. Of that figure, EUR 45.3 million corresponds to the oncology area. net attributable profit amounted to EUR 13.1 million, compared with EUR 11.3 million in 2013 (+16%).

Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Zeltia Reports Earnings Results for the Nine Months Ended September 2014

Zeltia reported earnings results for the nine months ended September 2014. For the period, the company's net sales grew by 7% year on year to EUR 116.9 million. Net profit amounted to EUR 17.5 million, a 24.3% increase compared with the same period in 2013. Positive performance was driven mainly by star oncology product Yondelis (trabectedin), net sales of which reached EUR 57 million, and the net sales of Biofarmacia increased by 7% to EUR 61.2 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZLIXF:US $4.59 USD 0.00

ZLIXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZLIXF.
View Industry Companies
 

Industry Analysis

ZLIXF

Industry Average

Valuation ZLIXF Industry Range
Price/Earnings 100.0x
Price/Sales 6.3x
Price/Book 13.5x
Price/Cash Flow 347.8x
TEV/Sales 5.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.